Lidocaine infusions and reduced opioid consumption—Retrospective experience in pediatric hematology and oncology patients with refractory pain. Issue 11 (15th July 2021)

• Record Type: Journal Article
• Authors: Anghelescu, Doralina L.; Morgan, Kyle J.; Frett, Michael J.; Wu, Diana; Li, Yimei; Han, Yuanyuan; Hall, Elizabeth A.
• Is Part Of: Pediatric blood & cancer. Volume 68:Issue 11(2021)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-07-15
• Subjects: Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29215
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: Despite a more robust experience with lidocaine infusions for pain management in adults and general pediatric population, there is limited evidence of efficacy of lidocaine infusions for pain management in patients with pediatric hematology and oncology diagnoses. Methods: Data pertaining to continuous intravenous lidocaine infusions prescribed between January 2009 and June 2019 were reviewed, including patients' demographic characteristics, hematology/oncology and pain diagnoses, concurrent pain medications, and lidocaine infusion dose regimens and duration. Pain scores and opioid consumption calculations based on morphine equivalent doses (mg/kg/day) of patient‐controlled analgesia were collected 1 day before infusion (D1), during infusion (D2), and 1 day after infusion (D3). Results: The mean opioid consumption on D3 was significantly lower than that on D2 ( p = .01). The pain scores on D3 were significantly lower than those on D1 when measured as average pain scores per 24 hours ( p < .001) or as single pain scores immediately before and after infusions ( p < .001). No significant associations were found between cumulative doses of lidocaine (loading dose plus total infusion dose) and either a decrease in the opioid consumption or a decrease in pain scores. Conclusions: In this retrospective series of pediatric hematology and oncology cases, we report positive outcomes in reducing opioid consumption and pain scores after lidocaine infusions. Prospective investigations designed in a collaborative, multi‐institutional fashion, including a variety of pediatric populations are needed to further investigate the efficacy of lidocaine infusions.